MicroTest gets $1.22 million contract

FEB. 25–AGAWAM, Mass.—MicroTest Laboratories (MTL) has received a $1.22 million contract to provide aseptic manufacturing support for the production of a series of recombinant vaccines against botulinum neurotoxins–one of the most poisonous natural biological substances known and pose a major bio-weapons threat.

The contract was awarded to MTL through DynPort Vaccine Co. (DVC; Frederick, Md.), a contractor of the Department of Defense, under the Joint Vaccine Acquisition Program (JVAP).

The JVAP is responsible for developing, licensing and stockpiling specific bio-defense vaccines and other products to protect armed forces personnel against potential bio-weapons agents.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.